Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

SDI Selected To Develop Monoclonal Antibodies

By Drug Discovery Trends Editor | March 1, 2010

SDI (Strategic Diagnostics Inc.), a leading provider of biotechnology-based products and services for a broad range of life science, food safety, and industrial applications, has been selected again by Science Applications International Corporation – Frederick (SAIC-F) to develop monoclonal antibodies for the National Cancer Institute’s “Clinical Proteomic Technologies for Cancer” initiative. The SDI monoclonal antibodies will serve as reference reagents for the scientific cancer community. 

SDI was selected for a third consecutive time as the key monoclonal antibody provider. The selection was based on SDI’s life sciences and antibody expertise, large-scale capacity, standardized processes, and fully-integrated quality management systems. The National Cancer Institute’s CPTC will extensively characterize these reagents consistent with their mission to make available high-quality reagents with baseline data to research scientists.

CPTC’s goal is to accelerate discovery and clinical research in cancer, using an integrated approach that assesses and optimizes proteomic technology measurement capabilities and develops universally accepted metrics to identify and minimize experimental variability from run-to-run, instrument-to-instrument, and lab-to-lab. CPTC aims to achieve this goal by optimizing existing platforms; developing innovative proteomic technologies and computational tools; and developing community reagents and resources. Its Proteomic Reagents & Resources component includes SOPs, data, proteins, and well-characterized, high-quality antibodies, whose performance characteristics will be observed at the Antibody Characterization Laboratory at NCI-Frederick (NCI-F), part of NCI-F’s Advanced Technology Program.

Commenting on the agreement, Mr. Fran DiNuzzo, SDI’s President and CEO, said, “SDI is proud to be a key supplier to this important large-scale cancer research initiative.  Being selected for a third consecutive year by SAIC-F underscores our belief that SDI’s expertise, quality, infrastructure, and capacity position us as a premier supplier of comprehensive antibody services. Moreover, as the study of proteins continues to increase in importance to the research community, and antibodies continue to be the most widely-used tools for understanding the molecular dynamics underlying disease, we anticipate a continued demand for SDI products and services.”  

Date: February 25, 2010
Source: Strategic Diagnostics Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE